ORYZON to present ORY-2001 new preclinical data of therapeutic activity at ACTRIMS-2017 in Orlando, Fl. USA

BARCELONA, SPAIN and CAMBRIDGE MA.

• The company will present a poster on February 24th 2017

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it will present new preclinical data of therapeutic activity in Multiple Sclerosis of ORY-2001, a novel epigenetic drug for the treatment of neurodegenerative diseases at the 2nd Annual Conference of the “Americas Committee for Treatment and Research in Multiple Sclerosis” (ACTRIMS) to be held in Orlando, Fl. USA on February 23 -25.

Click here to see the full Press Release